Your browser doesn't support javascript.
loading
Tumor Growth Rate in Spinal Giant Cell Tumors of Bone and Association With the Immune Microenvironment and Denosumab Treatment Responsiveness: A Multicenter Study.
Zheng, Bo-Wen; Zheng, Bo-Yv; Niu, Hua-Qing; Yang, Yi-Fan; Zhu, Guo-Qiang; Li, Jing; Zhang, Tao-Lan; Zou, Ming-Xiang.
Afiliação
  • Zheng BW; Department of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
  • Zheng BY; Musculoskeletal Tumor Center, Peking University People's Hospital, Peking University, Beijing, China.
  • Niu HQ; Department of Orthopedics Surgery, General Hospital of the Central Theater Command, Wuhan, China.
  • Yang YF; Department of Ophthalmology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Zhu GQ; Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Li J; Department of Orthopedics Surgery, Xiangya Hospital, Central South University, Changsha, China.
  • Zhang TL; Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Zou MX; Institute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Neurosurgery ; 92(3): 524-537, 2023 03 01.
Article em En | MEDLINE | ID: mdl-36409294
BACKGROUND: Currently, little is known about the prognostic value of tumor growth rate (TGR) in spinal giant cell tumors of bone (GCTB). OBJECTIVE: To investigate the correlation of TGR with clinicopathological features, immune microenvironment, prognosis, and response to denosumab treatment of spinal GCTB. METHODS: A total of 128 patients with spinal GCTB treated at 5 centers from 2011 to 2021 were included. TGR was assessed by 2 independent neuroradiologists using at least 2 preoperative thin-section magnetic resonance imaging scans at a minimum interval of 2 months. Immunohistochemistry was used to assess tumor-infiltrating lymphocyte subtypes for CD3, CD4, CD8, CD20, PD-1, PD-L1, and Foxp3. Then, these parameters were analyzed for their associations with patient outcomes (progression-free survival and overall survival), clinicopathological features, and denosumab treatment responsiveness. RESULTS: High TGR predicted both poor progression-free survival and overall survival (both P < .001). In addition, TGR was associated with postoperative neurological dysfunction ( P < .001), Enneking staging ( P = .016), denosumab treatment responsiveness ( P = .035), and the number of CD3 + ( P < .001), PD-1 + ( P = .009), PD-L1 + ( P < .001), and FoxP3 + tumor-infiltrating lymphocyte ( P = .02). Importantly, TGR outperformed the traditional Enneking, Campanacci, and American Joint Committee on Cancer staging systems in predicting the clinical outcomes of spinal GCTB. CONCLUSION: These data support the use of TGR as a reliable predictive tool for clinically relevant outcomes and response to denosumab therapy of spinal GCTB, which may be helpful in guiding prognostic risk stratification and therapeutic optimization of patients.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Tumor de Células Gigantes do Osso / Conservadores da Densidade Óssea Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Tumor de Células Gigantes do Osso / Conservadores da Densidade Óssea Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article